On January 31, 2019, Nuvectra Corporation announced that Scott F. Drees resigned from his positions as the Chief Executive Officer of the Company and as a member of the Board of Directors of the Company (the “Board”), effective January 31, 2019. Effective February 1, 2019, the Company appointed Dr. Parks, age 71, as the Company's Chief Executive Officer. Dr. Parks has served on the Board as a Class I Director since March 2016.

Because of his position as an executive officer of the Company, Dr. Parks will no longer be deemed an independent member of the Board and therefore will no longer serve as a member of the Board's Compensation and Organization Committee. Dr. Parks was previously the President and Chief Executive Officer of Analogic Corporation, from October 2016 to June 2018. Dr. Parks was also the Chief Executive Officer of Enovate Medical from July 2015 until October 2016.

Prior to joining Enovate Medical, Dr. Parks served as Chief Executive Officer of NDS Surgical Imaging, LLC from August 2011 to 2013 and Chairman and Chief Executive Officer of Urologix Inc. from May 2003 to February 2008. Prior to joining Urologix, Dr. Parks served as President and Chief Executive Officer of Marconi Medical Systems, which is currently part of Philips Medical Systems. Dr. Parks previously served as a director of Analogic Corporation and Enovate Medical. Previously, Dr. Parks served as a director of NDS Surgical Imaging, Urologix, EG&G Inc. (now PerkinElmer), St.

Jude Medical and Steady State Imaging. Effective February 1, 2019, the Board appointed Mr. Christopher G. Chavez, age 63, as an independent member of the Board and as a member of the Board's Compensation and Organization Committee. Mr. Chavez fills the vacancy left by Mr. Drees' resignation as a Class III Director and the vacancy on the Compensation and Organization Committee resulting from Dr. Parks appointment as Chief Executive Officer.

Mr. Chavez intends to stand for election as a Class III Director at the Company's 2019 annual meeting of stockholders to be held later this year. Mr. Chavez served as President, Chief Executive Officer and Chairman of TriVascular Technologies Inc. from April 2012 through its merger with Endologix Inc. in February 2016. Following the merger, he served as an Endologix Director from February 2016 through June 2018.

Mr. Chavez also served as President of the Neuromodulation Division of St. Jude Medical Inc. (NMD) from 2005 through 2011 following the acquisition of Advanced Neuromodulation Systems Inc. (ANSI) by St. Jude Medical in 2005.

Prior to that, he served as CEO, President and Director of ANSI from 1998 through 2005 and led ANSI and NMD through 14 years of profitable growth and innovation.